GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Core One Labs Inc (XCNQ:COOL) » Definitions » EV-to-EBITDA

Core One Labs (XCNQ:COOL) EV-to-EBITDA : -3.43 (As of Jul. 07, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Core One Labs EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Core One Labs's enterprise value is C$6.92 Mil. Core One Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-2.02 Mil. Therefore, Core One Labs's EV-to-EBITDA for today is -3.43.

The historical rank and industry rank for Core One Labs's EV-to-EBITDA or its related term are showing as below:

XCNQ:COOL's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.94
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-07), Core One Labs's stock price is C$0.145. Core One Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.050. Therefore, Core One Labs's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Core One Labs EV-to-EBITDA Historical Data

The historical data trend for Core One Labs's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core One Labs EV-to-EBITDA Chart

Core One Labs Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.82 -2.54 -1.79 -1.77 -0.38

Core One Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -1.45 -1.73 -4.66 -6.76

Competitive Comparison of Core One Labs's EV-to-EBITDA

For the Biotechnology subindustry, Core One Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Core One Labs's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Core One Labs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Core One Labs's EV-to-EBITDA falls into.


;
;

Core One Labs EV-to-EBITDA Calculation

Core One Labs's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.924/-2.018
=-3.43

Core One Labs's current Enterprise Value is C$6.92 Mil.
Core One Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Core One Labs  (XCNQ:COOL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Core One Labs's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.145/-0.050
=At Loss

Core One Labs's share price for today is C$0.145.
Core One Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Core One Labs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Core One Labs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Core One Labs Business Description

Traded in Other Exchanges
N/A
Address
1199 West Hastings Street, Suite 800, Vancouver, BC, CAN, V6E 3T5
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.
Executives
Geoffrey Balderson Director, Senior Officer
Joel Shacker Director, Senior Officer
Robert E.w. Hancock Director
Brad Eckenweiler 10% Security Holder, Director, Senior Officer